Outcomes of curative-intent radiotherapy in non-small cell lung cancer (NSCLC) patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD).
COPD
FEV1
ILD
NSCLC
Radiotherapy
Survival
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
30
07
2020
revised:
29
03
2021
accepted:
16
04
2021
pubmed:
27
4
2021
medline:
28
7
2021
entrez:
26
4
2021
Statut:
ppublish
Résumé
Outcomes of non-small cell lung cancer (NSCLC) patients with chronic obstructive pulmonary disease (COPD n = 587) and interstitial lung disease (ILD n = 34) treated with curative-intent radiotherapy were retrospectively investigated. Presence of ILD but not decreased forced expiratory volume in 1-second correlated with poor overall survival. Increased breathlessness and oxygen requirements after radiotherapy were observed in severe/very severe COPD and ILD.
Identifiants
pubmed: 33901563
pii: S0167-8140(21)06207-1
doi: 10.1016/j.radonc.2021.04.014
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
78-81Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest C. Faivre-Finn has declared research grants from AstraZeneca, MSD and Elekta and sits on the advisory boards of AstraZeneca and Pfizer. D. Woolf has declared travel grants, consultancy and speaker fees from AstraZeneca and travel grants from Roche. None of the other co-authors have any relevant conflicts of interest.